SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid is trending as investors are weighing the impact of Gravity SUV deliveries and new partnerships against concerns about potential dilution and the company's ability to meet production targets. Community discussions revolve around the company's long-term viability, particularly its cash burn rate and the effectiveness of recent marketing efforts. Sentiment is mixed, with some bulls touting the quality of Lucid's vehicles, while bears point to the company's financial challenges and competitive pressures within the EV sector.

Hyperliquid is a performant L1 optimized from the ground up. The vision is a fully onchain open financial system with user built applications interfacing with performant native components, all without compromising end user experience. The Hyperliquid L1 is performant enough to operate an entire ecosystem of permissionless financial applications – every order, cancel, trade, and liquidation happens transparently on-chain with block latency <1 second. The chain currently supports 100k orders / second. The Hyperliquid L1 uses a custom consensus algorithm called HyperBFT which is heavily inspired by Hotstuff and its successors. Both the algorithm and networking stack are optimized from the ground up to support the L1. The flagship native application is a fully onchain order book perpetuals exchange, the Hyperliquid DEX. Further developments include a native token standard, spot trading, permissionless liquidity, etc.

Hype

Hype Crypto is trending due to increased volume and renewed attention, particularly around its DEX and L1 ecosystem. The community is actively discussing potential breakout ranges and points to its potential as the 'house of all finance,' with some suggesting it could rival major platforms. Recent news of an AI bot launch and quantum-resistant infrastructure may also be driving interest.

Plasma is the layer 1 blockchain building the stablecoin infrastructure for a new global financial system.   It is purpose-built for global stablecoin payments, offering zero-fee USD₮ transfers and custom gas tokens to help realise the stablecoin promise of permissionless access to financial services for everyone, everywhere.   Plasma’s global payments coverage and inbound suite of products position it as the native chain for stablecoin payments.

Plasma

Plasma (XPL) is trending amid discussions about its recent listing on a Chinese exchange and potential benefits from the Fed's stablecoin initiatives, with some community members anticipating a pump. However, others are expressing concerns about a recent price drop and potential market manipulation. The project's utility in enabling stablecoin payments on the Bitcoin blockchain and connections to key players like Tether are also being highlighted.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance ($PSKY) is trending as discussions around a potential acquisition of Warner Bros. Discovery ($WBD) heat up, with reports suggesting a $60 billion bid involving private equity firms. Community members are debating the merits of the deal, potential regulatory hurdles, and whether CEO David Ellison can successfully navigate the complexities of a major media merger, while some express concern about overpaying for WBD and its debt.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

VIR is trending due to positive clinical trial data for its hepatitis delta treatment and the announcement of an upcoming Phase 3 registrational program, sparking optimism about its potential to address a rare and life-threatening condition. Community discussions revolve around the company's promising pipeline, strong cash position, and potential partnerships, particularly with GlaxoSmithKline, as well as recent insider activity and analyst ratings. Some investors also express concerns about dilution and the timing of data releases.

Ozarus is an AI-powered on-chain intelligence platform built on Solana, designed to protect traders and communities from scams, rugpulls, and high-risk tokens. The platform scans thousands of tokens daily, providing real-time risk scores, security audits, and token reliability insights. Its mission is to make Solana’s ecosystem safer, transforming trading from speculation-driven chaos into a transparent, data-backed environment.

Ozarus

Ozarus is gaining attention as community members discuss its potential for a significant move, citing bullish sentiment and strong support levels. The conversation highlights possible breakout opportunities and early entry points, with many referencing its presence on Phantom Wallet. The crypto asset is being watched for accumulation and a tightening price pattern that could precede a large swing.

Unum Group engages in the provision of financial protection benefits. Its services include disability, life, accident, critical illness, dental, vision, and other related services. It operates through the following segments: Unum US, Unum International, Colonial Life, Closed Block, and Corporate. The Unum US segment focuses on group disability, group life and accidental death and dismemberment products, and supplemental and voluntary lines of business. The Unum International segment engages in the operations of the UK business, which includes insurance for group long-term disability, group life, and supplemental lines of business that include dental, individual disability, and critical illness products. The Colonial Life segment includes insurance for accident, sickness, disability products, life products, and cancer and critical illness products. The Closed Block segment consists of individual disability, group and individual long-term care, and other insurance products no longer actively marketed. The Corporate segment refers to investment income on corporate assets and other corporate income and expenses not allocated to a line of business. The company was founded in 1848 and is headquartered in Chattanooga, TN.

Unum Group

Unum Group ($UNM) is trending due to recent analyst rating updates and target price increases, reflecting optimism about the company's financial outlook. The community is actively discussing potential breakout patterns and the stock's performance relative to the broader market. Positive analyst sentiment is driving interest in UNM, which operates within the insurance sector.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

PGY is trending as investors discuss the upcoming earnings report and the potential impact of recent news in the fintech sector. Community members are weighing insider activity, comparing PGY to competitors like UPST, and analyzing technical indicators for potential moves. Some believe PGY is undervalued, while others express concerns about the broader economic environment and its effect on consumer credit.

Ball Corp. engages in the supplies of aluminum packaging for the beverage, personal care, and household products industries. It operates through the following segments: Beverage Packaging North and Central America, Beverage Packaging South America, and Beverage Packaging Europe, Middle East and Africa (EMEA). The Beverage Packaging North and Central America segment includes multi-year supply contracts to fillers of carbonated soft drinks, beer, energy drinks, and other beverages. The Beverage Packaging South America segment includes beverage containers in South America, and the manufacture of substantially all the metal beverage containers in Brazil. The Beverage Packaging EMEA segment consists of metal beverage containers in Europe, and other packaging materials used by the European beer and carbonated soft drink industries. The company was founded by Edmund Burke Ball, Frank Clayton Ball, George A. Ball, Lucius Lorenzo Ball, and William Charles Ball in 1880 and is headquartered in Westminster, CO.

Ball Corp.

Recent analyst rating adjustments and price target reductions have spurred discussion around $BALL. The community is also closely monitoring the completed sale of Ball's Russian beverage packaging business and its impact on the company's financials. Additionally, new partnerships are being weighed against concerns about aluminum costs and demand changes.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

Biogen (BIIB) is trending due to a flurry of activity surrounding its pipeline and potential strategic moves, including a confirmed unsolicited acquisition proposal for Sage Therapeutics (SAGE). While some analysts express concerns about revenue and future growth, the community is discussing the potential for undervaluation and a turnaround, particularly with advancements in Alzheimer's treatments and new drug launches offsetting multiple sclerosis portfolio challenges. Chatter also highlights a C5aR license agreement and its potential read-through to InflaRx.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vera Therapeutics stock sinks following competitor’s successful trial

Investing.com -- Shares of  Vera Therapeutics  (NASDAQ:VERA) tumbled by 33% in premarket trading today after a Japanese competitor, Otsuka, reported positive results from a Phase 3 trial of a competing kidney disease therapy. Otsuka’s announcement indicated that its drug, sibeprenlimab, achieved a 51.2% reduction in proteinuria in the treatment of immunoglobulin A nephropathy (IgAN), surpassing the results from Vera’s own candidate, atacicept.

Shares of Vera Therapeutics, Inc. (VERA) were in the spotlight on Tuesday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-announces-refinancing-existing-oxford-debt">announced</a> that it has entered into a new credit facility providing for up to $500 million of term loans with its current partner, Oxford Finance LLC.The new credit facility will replace Vera’s existing $50 million credit facility. The initial funding of the new credit facility will be in a principal amount of $75 million and is expected to occur on June 4, 2025, the company said.The new credit facility features a lower interest rate, increasing capital availability and financial flexibility, the company stated.Vera Therapeutics is looking to submit a Biologics License Application to the U.S. Food and Drug Administration in the fourth quarter of this year for Atacicept. The company is looking forward to the potential commercialization of the investigational drug for the treatment of immunoglobulin A nephropathy (IgAN) in adults.IgA nephropathy, also known as Berger's disease, is a kidney disease where antibodies build up in the kidneys, causing inflammation and damage.Vera on Monday said that Atacicept achieved a 46% reduction from baseline in protein levels in the urine of 431 adults with IgA nephropathy being evaluated in a late-stage trial.VERA stock closed 67% higher on Monday on the news.On Stocktwits, retail sentiment around VERA stayed unmoved within the ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:624/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_03_at_8_05_39_AM_png_bf7adee158.webp" alt="VERA's Sentiment Meter and Message Volume as of 8:05 a.m. ET on June 3, 2025 | Source: Stocktwits" width="624" height="68"><figcaption>VERA's Sentiment Meter and Message Volume as of 8:05 a.m. ET on June 3, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user praised the company’s decisions.<stembedurl>https://stocktwits.com/US_Bull/message/616604119</stembedurl>Another expects the stock will hit $40 soon.<stembedurl>https://stocktwits.com/tomf95/message/616602882</stembedurl><a href="https://stocktwits.com/symbol/VERA">VERA stock</a> is down by 25% this year and by about 21% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/weride-partners-with-renault-for-autonomous-shuttle-service-at-the-french-open/chkr56IRbvO">WeRide Partners With Renault To Provide Autonomous Shuttle At The French Open, But Retail’s Not Excited</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40

The new credit facility features a lower interest rate, increasing capital availability and financial flexibility, the company stated.

Equity

The new credit facility features a lower interest rate, increasing capital availability and financial flexibility, the company stated.


Commit To Buy Vera Therapeutics At $25, Earn 12.7% Annualized Using Options

Investors eyeing a purchase of Vera Therapeutics Inc (VERA) shares, but cautious about paying the going market price of 38.14/share, might benefit from considering selling puts among the...

Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress

72-week data of atacicept in IgAN accepted as a best-ranked abstract Analysis of impact of atacicept on hematuria in IgAN accepted as a focused oral presentation BRISBANE, Calif., April 02...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Vera Therapeutics (VERA), Tyra Bioscience (TYRA) and Tenaya Therapeutics (TNYA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vera Therapeutics (VERA Research Report), Tyra Bioscience (TYRA...

Vera Therapeutics reports FY23 EPS ($2.25) vs ($3.35) last year

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatmentActively adding sites and...

Vera Therapeutics (VERA, $44.19) Aroon Indicator entered an Uptrend on March 12, 2024.

Over the last three days, A.I.dvisor has detected that VERA's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

Vera Therapeutics (VERA, $43.15) Aroon Indicator entered an Uptrend on March 11, 2024.

Vera Therapeutics (VERA, $44.3) Aroon Indicator entered an Uptrend on March 08, 2024.

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

VERA
Vera Therapeutics Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VERA News

VERAVera Therapeutics Inc - Ordinary Shares - Class A